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SUMMARY
Objective: Assess cognitive effects of adjunctive perampanel in adolescents.
Methods: In this double-blind study (ClinicalTrials.gov identifier: NCT01161524),
patients aged 12 to <18 years with partial-onset seizures despite receiving 1–3
antiepileptic drugs were randomized (2:1) to perampanel or placebo. Perampanel was
increased weekly in 2-mg increments to 8–12 mg/day (6-week titration; 13-weekmain-
tenance). Changes in neuropsychological outcomes were assessed at end of mainte-
nance: Cognitive Drug Research (CDR) System Global Cognition Score (primary end
point), five CDR System domain T-scores (secondary end points), letter fluency, cate-
gory fluency, and Lafayette Grooved Pegboard Test (LGPT).
Results: One hundred thirty-three patients were randomized. In the full analysis set,
there were no differences of perampanel (n = 79) vs. placebo (n = 44) in CDR System
Global Cognition Score (least squares mean change,0.6 vs. 1.6; p = 0.145), Quality of
Working Memory (1.1 vs. 2.0; p = 0.579), or Power of Attention (6.9 vs. 2.7;
p = 0.219). There were small differences with perampanel vs. placebo in other CDR
System domains: improvements in Quality of Episodic Memory (3.0 vs. 1.2;
p = 0.012), and worsening in Continuity of Attention (3.3 vs. 1.6; p = 0.013) and
Speed of Memory (0.3 vs. 7.0; p = 0.032). Letter fluency, category fluency, and LGPT
were not significantly different between groups. The most frequent adverse events
with perampanel were dizziness (30.6%) and somnolence (15.3%).
Significance: Perampanel did not differ from placebo in the global cognitive score, two
of five subdomains, and four other cognitive measures. Perampanel was worse on two
and better on one subdomain.
KEY WORDS: Adolescent, Antiepileptic drugs, Cognition, Partial seizures, Peram-
panel.
Antiepileptic drugs (AEDs) can produce adverse cogni-
tive and behavioral side effects, potentially compounding
effects of epilepsy on learning and development.1–3 Thus,
neuropsychological profiles of AEDs are important consid-
erations for treatment selection, particularly in children and
adolescents.
The Cognitive Drug Research (CDR) System is a set of
automated tests of cognitive function,4 available in >60 lan-
guages, and validated across several clinical populations.5–7
The CDR System has been used widely in clinical research,
including studies involving children and adolescents.8–15
Previously, the CDR System has demonstrated differ-
ences in the cognitive effects of carbamazepine versus
remacemide in a phase III trial16: measures of attention were
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significantly impaired by carbamazepine, relative to rema-
cemide, after 8 weeks of treatment in patients aged
12–75 years with newly diagnosed epilepsy16 (effects con-
sistent with previous observations1,3,17,18). Notably, prior to
dosing, study patients showed impairments on the CDR Sys-
tem Power of Attention domain compared with healthy vol-
unteers, with a Cohen’s d effect size of 0.63 in those aged
12–17 years.15
Perampanel is an a-amino-3-hydroxy-5-methyl-4-isoxa-
zole-propionic acid (AMPA) receptor antagonist19
approved in the United States and Europe for the adjunc-
tive treatment of partial-onset seizures, with or without
secondary generalization, and primary generalized tonic–
clonic seizures in patients with epilepsy aged 12 years
and older.20,21 There have been no prior studies that have
formally assessed the cognitive effects of perampanel.
The present 19-week study used the CDR System to
examine the cognitive effects of adjunctive perampanel in
adolescent patients with inadequately controlled partial-
onset seizures.
Methods
Standard protocol approvals, registrations, and patient
consents
This trial (Eisai Inc. protocol E2007-G000-235; Clini-
calTrials.gov identifier: NCT01161524) was conducted at
39 centers across 11 countries in North America, Europe,
Asia, and Australia. The trial was performed in accordance
with the Declaration of Helsinki, ICH-E6 Guideline CPMP/
ICH/135/95, European Directives 2005/28/EC and 2001/20/
EC, the U.S. Code of Federal Regulations, and the Pharma-
ceutical Affairs Law for studies conducted in Japan. The
trial protocol, amendments, and informed consent were
reviewed by national regulatory authorities in each country
and independent ethics committees or institutional review
boards for each site. Before participation, all patients gave
written assent and their legal guardian gave written
informed consent.
Patients
Patients were aged 12 to <18 years, with an intelligence
quotient (IQ) ≥7022 and a diagnosis of partial-onset seizures
according to the 1981 International League Against Epi-
lepsy (ILAE) Classification of Epileptic Seizures.23 Normal
interictal electroencephalography results were allowed if
other ILAE criteria were met and a progressive cause of epi-
lepsy was ruled out. Patients had at least one partial-onset
seizure during the previous 4 weeks, despite a stable regi-
men of 1–3 AEDs, which could include one enzyme-indu-
cing AED (carbamazepine or phenytoin).
Patients were excluded if they were pregnant or breast-
feeding, or had the following: primary generalized-onset
epilepsy or Lennox-Gastaut syndrome; a history of psy-
chogenic nonepileptic seizures in the previous 5 years; a
history of status epilepticus requiring hospitalization in
the previous 12 months, or seizure clusters; an unstable
psychiatric diagnosis or any comorbidities that could
affect cognitive function; any progressive central nervous
system (CNS) disease; epilepsy surgery scheduled in the
following 6 months; participated in previous trials
involving perampanel; multiple drug allergies or a severe
reaction to AEDs; used phenobarbital, primidone, or ben-
zodiazepines within 4 weeks of the study; felbamate
within 8 weeks (unless they were receiving a stable dose
and had been taking felbamate for at least 2 years, with-
out hepatic or bone marrow dysfunction), or vigabatrin
within 5 months; any history of vigabatrin-associated
clinically significant abnormalities in visual perimetry
testing; used any other drugs that affected the CNS
where the dose had not been stabilized for at least
4 weeks; a vagus nerve stimulator (VNS) implanted
within 5 months of the study (if implanted earlier, VNS
counted as one of the 1–3 permitted AEDs; stimulatory
parameters must not have changed within 4 weeks of the
study).
Study design
This was a randomized, double-blind, placebo-con-
trolled, parallel-group phase II study. Following a 1-week
baseline, patients were randomized (2:1) to receive once-
daily oral perampanel (Fycompa, Eisai Co. Ltd, Kawa-
shima, Japan) or matching placebo tablets during a 6-week
titration period and 13-week maintenance period. Patients
were assigned to perampanel or placebo using a computer-
generated randomization scheme. Patients and study per-
sonnel were blinded to treatment during the randomized
period.
Perampanel was started at 2 mg/day and uptitrated
weekly, in 2 mg increments, to a target dose range of 8–
12 mg/day. According to investigator judgment, patients
experiencing intolerable adverse events could have dose
Key Points
• Adolescents with inadequately controlled partial-onset
seizures (n = 133) were randomized to adjunctive per-
ampanel or placebo under double-blind conditions
• Perampanel was increased weekly in 2 mg increments,
to a target of 8–12 mg/day (6-week titration; 13-week
maintenance)
• The primary outcome was change in cognition from
baseline to end of treatment, as assessed by a standard-
ized computerized test battery
• Adjunctive perampanel did not significantly differ
from placebo in in the global cognitive score, two of
five subdomains, and four other cognitive measures,
but was worse on two and better on one subdomain
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reductions, with subsequent increases if tolerability
improved. Patients not tolerating perampanel 2 mg/day dis-
continued treatment.
Patients completing the maintenance period could receive
perampanel in an open-label extension. Alternatively,
patients participated in a 4-week follow-up period after
stopping treatment.
Neuropsychological assessments
The CDR System was included in the Pediatric Investiga-
tional Plan for perampanel, which was approved by the
Pediatric Committee of the European Medicines Agency. It
is an automated system, with task stimuli presented on the
screen of a notebook computer for patients to provide
responses using a simple response box containing buttons
marked “YES” and “NO.” The CDR System was selected as
the primary assessment tool for this study as a means to
standardize methodology, and because it had validated lan-
guage versions appropriate for each of the 11 countries in
which the study was run. In addition, it has been used previ-
ously to detect cognitive effects of AEDs in pediatric
patients with epilepsy.15
In the present study, cognitive assessments using the
CDR System were conducted at week 0 (baseline, prior to
study drug administration), week 10, and the end of treat-
ment (week 19, or last observation carried forward for nine
patients who underwent a final assessment at the time of
early termination). Nine tests were administered at each
time point: three to assess attention, information processing,
and vigilance (simple reaction time, choice reaction time,
and digit vigilance), three to assess verbal episodic memory
(immediate word recall, delayed word recall, and word
recognition), two to assess articulatory and spatial working
memory (numeric working memory and spatial working
memory), and one to assess nonverbal episodic memory
(picture recognition). Tests were administered by a trained
individual, using standardized instructions given prior to
each computerized test, and could be completed within
20 min. The CDR System has >50 parallel forms of the vari-
ous tests, ensuring that different stimuli are used each time a
patient performs a task with the System.4 Patients per-
formed all tests twice during the screening period prior to
the baseline visit, to ensure familiarity and help overcome
training effects.24
The primary outcome was change in the CDR System
Global Cognition Score from baseline to end of treatment.
Key secondary end points were changes in the five core
CDR System domains: (1) Power of Attention (a measure of
focused attention and information processing, derived from
speed scores for simple reaction time, choice reaction time,
and digit vigilance); (2) Continuity of Attention (a measure
of sustained attention, derived from accuracy scores for
choice reaction time and digit vigilance); (3) Quality of Epi-
sodic Memory (a measure of the ability to encode, store, and
retrieve verbal and nonverbal episodic information derived
from accuracy scores for immediate word recall, delayed
word recall, word recognition, and picture recognition); (4)
Quality of Working Memory (a measure of the ability to
hold numeric and spatial information in the working mem-
ory derived from sensitivity scores for numeric working
memory and spatial working memory); and (5) Speed of
Memory (a measure of the time needed to retrieve informa-
tion from episodic and working memory derived from speed
scores for numeric working memory, spatial working mem-
ory, word recognition, and picture recognition).25 Z-scores
were calculated for each domain using normative data from
the CDR System database for the age range of the study
population. Specifically, Z-scores were calculated by sub-
tracting each patient’s domain score from the normative
population mean of that domain and dividing the result by
the standard deviation (SD) of the normative population
mean. Z-scores were converted into T-scores by multiplying
by 50 and adding 50. Power of Attention and Speed of
Memory T-scores were also multiplied by1, so that for all
domains, greater T-scores reflected superior cognitive func-
tion. T-scores ranged from 0 to 100, with a mean of 50 and
an SD of 10. The CDR System Global Cognition Score was
created by adding the T-scores for the five domains.
Additional secondary end points included changes in
language and manual dexterity from baseline to end of
treatment. Language was assessed using the Controlled
Oral Word Association Test letter fluency test (in which
patients list as many words as they can in 1 min that start
with a given letter), and a category fluency test (in which
patients list as many words as they can in 1 min that
relate to a given topic)26; numbers of correct items were
summarized, with improvements reflected by increased
scores. Manual dexterity was assessed using the Lafayette
Grooved Pegboard Test (LGPT)26; time to complete the
LGPT was reported for each hand, with improvements
reflected by reductions in time.
Safety assessments
Throughout the study, treatment-emergent adverse events
(TEAEs), hematology, blood chemistry, urine values, and
vital signs were monitored, and electrocardiography studies
and physical examinations were performed. TEAEs were
graded as mild (discomfort noticed, but no disruption of nor-
mal daily activity), moderate (discomfort sufficient to
reduce or affect normal daily activity), or severe (incapaci-
tating, with inability to work or to perform normal daily
activity). Serious TEAEs included those that were life-
threatening, or resulted in hospitalization, persistent or sig-
nificant disability/incapacity, or death.
Other assessments
Further end points relating to safety (growth and develop-
ment outcomes, photosensitivity, and TEAEs of special
interest), efficacy, pharmacokinetics, behavior, and quality
of life will be reported separately.
Epilepsia, 57(2):243–251, 2016
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Statistical analyses
The a priori primary end point was the change in the
CDR System Global Cognition Score from baseline to
end of treatment. Analyses of the individual CDR system
domain scores are secondary end points meant to evalu-
ate sensitivity of the primary end point. Letter fluency
test, category fluency test, and LGPT are additional cog-
nitive tests. The study is sufficiently powered to show
the effect in the primary end point of Global cognitive
score. All other end points are supportive. Hence no
adjustment for multiplicity was planned. The other end
points also offer important safety assessments; therefore,
assessing these variables without multiplicity adjustment
is a more conservative approach, which is appropriate
for safety measures.
It was preplanned that all neuropsychological assess-
ments would be based on the full analysis set (FAS) for cog-
nition, which comprised all randomized patients who
received study drug, had baseline cognition data, and had at
least one CDR System domain assessment at or after week
10. For additional information, CDR System Global Cogni-
tion Scores are also presented for the per-protocol popula-
tion (all patients in the FAS who sufficiently complied with
the protocol) and completers’ population (all randomized
patients who completed the study and were assessed at week
19).
Changes in CDR System scores were analyzed by analy-
sis of covariance (ANCOVA), with baseline score and age
as covariates, and gender, treatment, and region as factors
(region based on pooling of countries according to their geo-
graphic location: Europe, Asia, or North America). A two-
sided 95% confidence interval (CI) was created on the least
squares (LS) mean for the difference between the placebo
and perampanel groups. A difference of five T-score units
in the CDR System Global Cognition Score was prespeci-
fied as clinically meaningful. This is comparable to the
effect of 0.08 g/dL alcohol (legal limit for driving in the
United Kingdom and U.S.A.) on the CDR System Global
Cognition Score (4.4 units), but more conservative than the
effects of lorazepam 1 mg (9.4 units) or lorazepam 2 mg
(17.7 units).27,28
The power calculation identified that a sample size of 117
patients was required (with an additional 10% allowed to
account for study dropouts). This provided 80% power to
detect a difference of five T-score units in CDR SystemGlo-
bal Cognition Score between placebo and perampanel,
using a between-group t-test at a 5% two-sided level of sig-
nificance. Based on this sample size, it was assumed that a
two-sided 95% CI for the difference in mean would extend
by <3.5 units on each side from the observed difference in
mean.
Changes in letter and category fluency were compared
for the two treatment arms post hoc by ANCOVA, with
baseline scores as covariates. Changes in time to complete
the LGPT test were compared post hoc by log-rank test.
The safety analysis set consisted of all randomized
patients who received study drug and had at least one post-
dose safety assessment.
Results
Patient disposition, demographics, and treatment
The first patient was enrolled in September 2010, and the
last patient visit occurred in June 2013. Of 154 screened
Figure 1.
Patient disposition.
Epilepsia ILAE
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patients, 133 were randomized and received treatment
(placebo, n = 48; perampanel, n = 85), and 119 completed
the study (placebo, n = 43 [89.6% of randomized and trea-
ted patients]; perampanel, n = 76 [89.4% of randomized
and treated patients]; Fig. 1). There were 76 patients aged
12 to <15 years and 57 patients aged 15 to <18 years.
Patient demographics and baseline characteristics were
largely balanced between groups (Table 1). Although not
statistically significant, possible exceptions were that,
compared with the placebo group, more perampanel-treated
patients had an IQ above 115 (12.5% vs. 21.2%) and more
had a history of seizures with secondary generalization
(39.6% vs. 51.8%) (p = 0.171 and p = 0.169, respectively,
based on post hoc Cochran-Mantel-Haenszel tests, adjusted
for region).
Most patients received treatment for >18 weeks with pla-
cebo (85.4%) or perampanel (85.9%). The median/mean
(SD) daily dose of perampanel was 6.0/6.2 (1.1) mg during
Table 1. Patient demographics and baseline characteristics (safety analysis set)
Placebo (n = 48) Perampanel (n = 85) Total (n = 133)
Mean age, years (SD) 14.3 (1.9) 14.3 (1.7) 14.3 (1.8)
Female, n (%) 20 (41.7) 33 (38.8) 53 (39.8)
Mean height, cm (SD) 161.2 (12.2) 161.8 (11.1) 161.6 (11.5)
Mean weight, kg (SD) 55.9 (17.3) 54.7 (17.1) 55.2 (17.1)
Mean BMI, kg/m2 (SD) 21.1 (4.4) 20.6 (4.9) 20.8 (4.7)
Race, n (%)
White 28 (58.3) 48 (56.5) 76 (57.1)
Black 1 (2.1) 3 (3.5) 4 (3.0)
Asian 19 (39.6) 32 (37.6) 51 (38.3)
Other 0 (0.0) 2 (2.4) 2 (1.5)
Country, n (%)
Australia 1 (2.1) 0 (0.0) 1 (0.8)
Belgium 2 (4.2) 2 (2.4) 4 (3.0)
Czech Republic 1 (2.1) 0 (0.0) 1 (0.8)
Hungary 7 (14.6) 17 (20.0) 24 (18.0)
India 12 (25.0) 23 (27.1) 35 (26.3)
Republic of Korea 3 (6.3) 3 (3.5) 6 (4.5)
Latvia 8 (16.7) 11 (12.9) 19 (14.3)
Poland 2 (4.2) 4 (4.7) 6 (4.5)
Spain 2 (4.2) 7 (8.2) 9 (6.8)
Thailand 4 (8.3) 6 (7.1) 10 (7.5)
U.S.A. 6 (12.5) 12 (14.1) 18 (13.5)
Mean IQ score (SD) 100.5 (12.9) 101.6 (14.7) 101.2 (14.0)
IQ score, group, n (%)
70–84 5 (10.4) 12 (14.1) 17 (12.8)
85–115 37 (77.1) 55 (64.7) 92 (69.2)
>115 6 (12.5) 18 (21.2) 24 (18.0)
Seizure type, n (%)
Simple partial without motor signs 9 (18.8) 12 (14.1) 21 (15.8)
Simple partial with motor signs 15 (31.3) 31 (36.5) 46 (34.6)
Complex partial 35 (72.9) 59 (69.4) 94 (70.7)
Partial with secondary generalization 19 (39.6) 44 (51.8) 63 (47.4)
Generalized seizures 1 (2.1)a 0 1 (0.8)
Unclassified epileptic seizures 0 2 (2.4) 2 (1.5)
Number of concomitant AEDs (%)
1 18 (37.5) 35 (41.2) 53 (39.8)
2 23 (47.9) 35 (41.2) 58 (43.6)
3 7 (14.6) 15 (17.6) 22 (16.5)
Most commonly administered concomitant
AEDs (>10% of patients), n (%)
Valproic acid 23 (47.9) 33 (38.8) 56 (42.1)
Levetiracetam 9 (18.8) 37 (43.5) 46 (34.6)
Lamotrigine 12 (25.0) 18 (21.2) 30 (22.6)
Oxcarbazepine 11 (22.9) 16 (18.8) 27 (20.3)
Carbamazepine 10 (20.8) 13 (15.3) 23 (17.3)
Topiramate 8 (16.7) 13 (15.3) 21 (15.8)
Lacosamide 5 (10.4) 10 (11.8) 15 (11.3)
BMI, body mass index; IQ, intelligence quotient; SD, standard deviation.
aThis patient had a medical history of both complex partial and generalized seizures but with complex partial seizures as the primary diagnosis.
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the titration period and 10.0/9.6 (2.1) mg during the mainte-
nance period. The dose received for the longest duration
was 8–12 mg in most cases (83.5%).
Neuropsychological outcomes
In the FAS, LS mean change in CDR System Global
Cognition Score between baseline and end of treatment
was 1.6 with placebo (n = 44) and 0.6 with perampanel
(n = 79; Table 2). These outcomes were not statistically
significantly different (difference in LS mean 2.2, 95%
confidence interval [CI] 5.2 to 0.8; p = 0.145). Further-
more, the mean difference between the placebo and per-
ampanel groups was less than the prespecified level of
five T-score units and was therefore not considered clini-
cally meaningful. In the per-protocol population, the LS
mean change in CDR System Global Cognition Score was
2.1 with placebo (n = 44) and 0.4 with perampanel
(n = 72; difference in LS mean 1.7, 95% CI 4.7 to
1.3; p = 0.269). In the completers’ population, the
LS mean change in CDR System Global Cognition Score
was 1.4 with placebo (n = 40) and 0.4 with perampanel
(n = 74), which approached statistical significance (differ-
ence in LS mean 1.7, 95% CI 3.5 to 0.0; p = 0.050),
but remained <5 T-score units.
Similarly, there were no apparent differences between
placebo and perampanel in terms of changes in the T-scores
of the CDR System domains of Power of Attention or Qual-
ity of Working Memory (FAS; Table 2). However, there
were small but significant differences in terms of Continuity
of Attention (increased with placebo, but reduced with per-
ampanel), Quality of Episodic Memory (reduced with pla-
cebo, but increased with perampanel), and Speed of
Memory (compared with placebo, there was a smaller
reduction over time with perampanel).
There were minimal changes in letter and category
fluency scores, and time to complete the LGPT test,
between baseline and end of treatment in both the pla-
cebo and perampanel groups (FAS; Table 3). Differences
between the treatment groups were not statistically sig-
nificant.
Safety outcomes
The safety analysis set included 133 patients (placebo,
n = 48; perampanel, n = 85). Perampanel was generally
well tolerated, with no clinically important mean changes in
laboratory values, vital signs, or electrocardiography
parameters. The most frequently reported TEAEs with per-
ampanel were dizziness and somnolence (Table 4).
Aggressive behavior was reported in one of 48 placebo-
treated patients (2.1%) and 7 of 85 perampanel-treated
patients (8.2%). Three perampanel-treated patients had
aggression requiring treatment modification (dose reduced
Table 2. Changes in CDR SystemGlobal Cognition Score and domain T-scores between baseline and end of
treatmenta (full analysis set)
Placebo (n = 44) Perampanel (n = 79) Difference in LS mean (95%CI) for perampanel vs. placebo
CDR SystemGlobal Cognition Score
Baseline mean score (SD) 41.2 (10.7) 40.8 (13.0) –
End of treatment mean score (SD) 42.2 (11.8) 39.7 (13.5) –
LS mean change (SE) 1.6 (1.3) 0.6 (1.0) 2.2 (5.2 to 0.8); p = 0.145
Power of Attention
Baseline mean score (SD) 24.7 (19.4) 24.9 (23.9) –
End of treatment mean score (SD) 22.0 (25.6) 17.9 (24.6) –
LS mean change (SE) 2.7 (3.0) 6.9 (2.3) 4.2 (11.0 to 2.6); p = 0.219
Continuity of Attention
Baseline mean score (SD) 53.1 (9.1) 52.8 (7.5) –
End of treatment mean score (SD) 54.1 (6.4) 50.7 (9.2) –
LS mean change (SE) 1.6 (1.2) 1.7 (0.9) 3.3 (6.0 to0.7); p = 0.013
Quality of Episodic Memory
Baseline mean score (SD) 51.6 (12.9) 52.1 (14.4) –
End of treatment mean score (SD) 50.9 (12.7) 55.5 (15.1) –
LS mean change (SE) 1.2 (1.5) 3.0 (1.1) 4.2 (0.9–7.5); p = 0.012
Quality ofWorking Memory
Baseline mean score (SD) 52.2 (8.6) 50.7 (11.4) –
End of treatment mean score (SD) 53.4 (9.9) 52.4 (9.4) –
LS mean change (SE) 2.0 (1.5) 1.1 (1.2) 1.0 (4.4 to 2.5); p = 0.579
Speed of Memory
Baseline mean score (SD) 24.2 (23.0) 23.4 (28.1) –
End of treatment mean score (SD) 29.6 (20.8) 22.2 (34.2) –
LS mean change (SE) 7.0 (2.7) 0.3 (2.1) 6.6 (12.7 to0.6); p = 0.032
CDR System, Complete Drug Research System; CI, confidence interval; LS, least squares; SD, standard deviation; SE, standard error.
Statistical comparisons based on analysis of covariance, with baseline score and age as covariates, and region, treatment, and gender as factors.
aHigher scores indicate better cognitive function.
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from 8 to 6 mg due to moderate aggression, n = 2; dose
increased from 8 to 10 mg when aggression changed in
intensity frommoderate to mild, n = 1), and two had serious
aggression (aggression treated separately; patients recov-
ered with no change to study treatment), although no cases
necessitated discontinuation. No homicidal ideation/threats
or suicidal ideation/behaviors were reported.
Discussion
Although AED treatment is a known potential contributor
to cognitive dysfunction, cognition studies in pediatric epi-
lepsy have been inadequate.2 For example, topiramate has
been associated with cognitive impairment in adults,29 and
treatment-limiting cognitive impairment/sedation in a retro-
spective study of children and adolescents,30 yet there have
been no objective assessments of cognitive function in a
pediatric population treated with this AED. Nonetheless,
some recent pediatric studies using appropriate measures of
cognition have been reported. One of the first demonstrated
no difference between adjunctive placebo and levetiracetam
in the Leiter International Performance Scale-Revised on
Attention and Memory, in children aged 4–16 years with
partial-onset seizures.31
In the present 19-week study, adjunctive perampanel did
not have any significant overall cognitive effect in adoles-
cent patients with inadequately controlled partial-onset sei-
zures. Specifically, compared with placebo, adjunctive
perampanel resulted in a nonsignificant LS mean difference
of 2.2 (95% CI 5.2 to 0.8; p = 0.145) in the change in
CDR System Global Cognition Score from baseline to end
of treatment, which was less than the five T-score units pos-
tulated to be clinically meaningful.
The individual CDR System domain scores suggested
possible benefits for Quality of Episodic Memory and
possible worsening of Continuity of Attention and Speed
of Memory with perampanel compared with placebo,
although these differences were small. Nonetheless, the
possible beneficial effect of perampanel on episodic
memory is novel compared with other AEDs, and war-
rants further investigation to confirm this finding and
identify the underlying mechanism. There were no sig-
nificant differences between perampanel and placebo in
the other CDR System domains (Power of Attention and
Quality of Working Memory).
Measures of language (letter and category fluency)
and manual dexterity (LGPT) were also not significantly
different for placebo and perampanel. However, it
Table 3. Changes in letter and category fluency scores,a and time to complete the Lafayette Groove Pegboard Test,b
between baseline and end of treatment (full analysis set)
Placebo (n = 44) Perampanel (n = 79) Perampanel vs. placebo
Letter fluency score
Baseline, n 44 76 –
Mean score (SD) 23.4 (9.5) 28.7 (12.8) –
End of treatment, n 44 76 –
Mean score (SD) 24.0 (10.6) 29.3 (13.6) –
LS mean for change (SE) 0.206 (1.069) 0.854 (0.808) Difference in LS mean (95% CI):
0.648 (2.034, 3.330); p = 0.633
Category fluency score
Baseline, n 44 76 –
Mean score (SD) 14.4 (5.15) 15.4 (4.6) –
End of treatment, n 44 76 –
Mean score (SD) 14.7 (5.4) 14.8 (4.4) –
LS mean for change (SE) 0.113 (0.490) 0.447 (0.372) Difference in LS mean (95% CI):
0.560 (1.782, 0.661); p = 0.365
LGPT: dominant hand
Baseline, n 44 75 –
Mean time, s (SD) 86.8 (37.7) 85.0 (22.1) –
End of treatment, n 44 79 –
Mean time, s (SD) 77.6 (19.9) 84.9 (20.2) –
Change 9.2 (28.8) 0.2 (17.2) p = 0.143
LGPT: nondominant hand
Baseline, n 44 74 –
Mean time, s (SD) 99.5 (47.1) 105.9 (46.5)c –
End of treatment, n 43 79 –
Mean time, s (SD) 91.7 (34.7) 102.4 (37.8)c –
Change 7.7 (28.8) 2.5 (25.0) p = 0.109
CI, confidence interval; LGPT, Lafayette Groove Pegboard Test; LS, least squares; s, second; SD, standard deviation; SE, standard error.
aHigher scores indicate better language skills; statistical comparisons based on analysis of covariance, with baseline score as a covariate.
bLower scores (shorter times) indicate better manual dexterity; statistical comparisons based on log-rank test.
cOne patient was unable to complete the test in 300 s, and so a time of 300 s was recorded.
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should be noted that statistical analyses of these mea-
sures were conducted post hoc, and the study was not
powered to investigate the statistical significance of
these comparisons.
In addition, perampanel was well tolerated by adolescent
patients, with a safety profile consistent with the findings of
a subgroup analysis of pooled phase III data from adolescent
patients.32,33 Aggressive behavior was reported in 2.1% (1/
48) of placebo-treated patients and 8.2% (7/85) of peram-
panel-treated patients. Although dose reduction was
required in some patients, none required discontinuation,
and no homicidal ideation/threats or suicidal ideation/be-
haviors were reported. Similar findings were observed
across three phase III randomized, double-blind, placebo-
controlled studies in patients with partial-onset seizures,
with aggression reported in 8.2% (8/98) of adolescent
patients treated with perampanel and none (0/45) treated
with placebo.34
Limitations of the study include the relatively limited
neuropsychological battery. In addition, although the study
was of sufficient duration to allow habituation to AED
effects as opposed to acute-dose studies, it was not long
enough to assess potential long-term effects on factors such
as school performance. The results from the open-label
long-term extension to this study will be reported sepa-
rately. Another limitation is that the sensitivity of the CDR
to AEDs was established in a monotherapy trial. An adjunc-
tive trial may be less sensitive to identify cognitive effects
of AEDs because the baseline medications may produce
adverse cognitive effects resulting in floor effects. How-
ever, differential effects were seen on three of the five CDR
subdomains. Further studies may be useful to explore cogni-
tive effects using more detailed neuropsychological batter-
ies, and to confirm the possible benefits of perampanel on
episodic memory.
Overall, it is important to recognize that the effectiveness
of an AED is a combination of efficacy and tolerability. One
of the major factors determining tolerability is the frequency
and severity of drug-induced adverse cognitive effects, as
such effects can have a detrimental impact on patient quality
of life.35 Indeed, these drug-related effects can outweigh the
positive effects of seizure reduction, short of achieving
complete seizure freedom. The finding of a favorable cogni-
tive profile for perampanel is, therefore, important in this
regard. Additional studies are needed to compare peram-
panel with other AEDs.
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